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7 Abstract
8 Purpose: Successful therapy of patients with prostate cancer is highly dependent on reliable diagnostic
9 and prognostic biomarkers. Brachyury is considered a negative prognostic factor in colon and lung cancer;
10 however, there are no reports on Brachyury’s expression in prostate cancer.
11 Experimental Design: In this study, we aimed to assess the impact of Brachyury expression in prostate
12 tumorigenesis using a large series of human prostate samples comprising benign tissue, prostate intrae-
13 pithelial neoplasia (PIN) lesions, localized tumor, and metastatic tissues. The results obtained were
14 compared with what can be inferred from the Oncomine database. In addition, multiple in vitro models
15 of prostate cancer were used to dissect the biologic role of Brachyury in prostate cancer progression.
16 Results:We found that Brachyury is significantly overexpressed in prostate cancer andmetastatic tumors
17 when compared with normal tissues, both at protein and at mRNA levels. Brachyury expression in the
18 cytoplasm correlates with highly aggressive tumors, whereas the presence of Brachyury in the nucleus is
19 correlated with tumor invasion. We found that Brachyury-positive cells present higher viability, prolifer-
20 ation, migration, and invasion rates than Brachyury-negative cells. Microarray analysis further showed that
21 genes co-expressed with Brachyury are clustered in oncogenic-related pathways, namely cell motility, cell-
22 cycle regulation, and cell metabolism.
23 Conclusions: Collectively, the present study suggests that Brachyury plays an important role in prostate
24 cancer aggressiveness and points, for the first time, to Brachyury as a significant predictor of poor prostate
25 cancer prognosis.Ourwork paves theway for future studies assessing Brachyury as a possible prostate cancer
26 therapeutic target. Clin Cancer Res; 1–13. 2014 AACR.
27
28
29
30 Introduction
31 Prostate cancer is the most common malignancy in men
32 and the second leading cause of cancer-related deaths
33 worldwide. In the United States, prostate cancer is the
34 leading cause of cancer-related mortality (1). Despite
35 advances in prevention and early detection, refinements in
37surgical techniques, and improvements in adjuvant radio-
38therapy and chemotherapy, metastasis is a frequent event
39that hinders patients’ cure. One important mechanism that
40governs cancer cell invasion and further metastasis is cel-
41lular epithelial–mesenchymal transition (EMT; ref. 2). The
42EMT is a complex process that involves downregulation of
43epithelial markers, such as E-cadherin, and upregulation of
44mesenchymal markers, such as Snail, Slug, andN-cadherin,
45among other alterations. These lead to loss of epithelial cell
46polarity and acquisition of more motile and invasive phe-
47notypes, promoting cancer cell dissemination into distant
48sites (3).
49The T-box protein Brachyury is a transcription factor
50required for mesoderm specification during embryo devel-
51opment (4), which is widely expressed in notochord cells
52and plays a pivotal role in notochord development (5).
53Recently, Brachyury was associated with tumor aggres-
54siveness in several tumor types (6–11) and was found to
55be a significant predictor of poor prognosis in early colon
56cancer (8) and lung cancer (6). In vitro studies suggested that
57these associations are driven by EMT, accomplished by
58increased migratory and invasion capacity (12–14) and
59increased cancer stem cell features (10, 11). Different stud-
60ies have reported divergent effects of Brachyury expression
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63 on cell proliferation. In lung cancer cell lines, it was dem-
64 onstrated that Brachyury blocks cell-cycle progression and,
65 therefore, mediates tumor resistance (15). However, in
66 adenoid cystic carcinoma cells, Brachyury promoted tumor
67 growth and metastasis formation in vivo (11). Therefore,
68 despite the described oncogenic role of Brachyury, some
69 authors suggest that it can also act as a tumor suppressor
70 gene (16).
71 A recent in vitro study showed that Brachyury overexpres-
72 sion promoted cell invasion in prostate cancer, probably
73 mediated by TGFb1 production (13). However, knowledge
74 on the role of Brachyury in prostate cancer progression
75 remains very limited. In the present work, we investigated
76 the clinical impact of Brachyury expression in a well-char-
77 acterized cohort of human prostate cancer samples and
78 evaluated its biologic role in prostate cancer cell prolifera-
79 tion and invasiveness. We report that Brachyury is over-
80 expressed in primary prostate cancer and metastatic tissues
81 and that Brachyury expression is correlated with classic
82 parameters of prostate cancer progression and aggres-
83 siveness. We also provide data that suggest Brachyury as a
84 therapeutic target in prostate cancer treatment.
85 Materials and Methods
86 Tissue samples
87 Prostate tissues were obtained from 480 patients with a
88 64-year-old median age (range, 46–74), who performed
89 radical prostatectomy as primary therapy (no preceding
90 hormonal or radical therapy) from 1993 to 2010 at Centro
91 Hospitalar do Porto and Centro Hospitalar do Alto Ave-
92 Guimar~aes, Portugal. The series included a total of 211
93 nonneoplastic tissue, 143 high-grade prostate intraepithe-
94 lial neoplasia (PIN) lesions, and 409 primary prostate
95 carcinomas. High-grade PIN lesions and nonneoplastic
96 tissues were obtained from tumor adjacency. Thirteen nor-
97 mal samples were obtained from patients undergoing rad-
99ical cystoprostatectomy for transitional cell carcinoma of
100the bladder. Nine metastatic tissues were obtained from
101patients who performed biopsies for metastatic prostate
102cancer. Formalin-fixed and paraffin-embedded tumors and
103clinicopathologic data were retrieved from the files of the
104Department of Pathology of both the hospitals. Tumors
105were staged using the 2010pTNM American Joint Commit-
106tee on Cancer (AJCC) classification (17) and graded using
107the Gleason grading system 2005 (18). Samples were orga-
108nized into tissue microarray (TMA) as previously described
109(19). The histologic features of the sampled areas were
110representative of the final Gleason score for the case. The
111study was previously approved by Local Ethical Review
112Committee of Centro Hospitalar do Porto (ref. no. 017/
11308-010-DEFI/015-CES).
114Cell lines and cell culture
115Fivehumanprostate cell lines representing in vitromodels
116of prostate cancer progression and aggressiveness, PNT2,
11722RV1, LNCaP, PC3, and DU145 (ATCC), were grown in
118RPMI-1640medium supplementedwith 10%FBS (GIBCO,
119Invitrogen) and 1% penicillin/streptomycin (P/S; GIBCO,
120Invitrogen). PNT2 is a normal prostate cell line, 22RV1 is a
121prostate epithelial carcinoma cell line, LNCaP is derived
122from lymph nodemetastasis and is hormone-sensitive, and
123DU145 and PC3 cell lines are derived from brain and bone
124metastasis, respectively, and represent poorly differentiated
125tumors.
126Brachyury overexpression and knockdown in prostate
127cancer cell lines
12822RV1 and DU145 cell lines were transfected with full-
129length human Brachyury in pcDNA4/TO vector, thus des-
130ignated pcBrachyury. The empty vector (designated 4/TO)
131was used as control (12). Stable 22RV1 and DU145 cell
132poolswithpcBrachyury expressionwereobtained following
133treatment with 50 mg/mL zeocin (Invitrogen). PC3 cells
134were transfected with Brachyury-specific shRNA construct
135(shBrachy.1) or empty vector alone (pLKO.1; Sigma-
136Aldrich) using X-tremeGENE HP transfection reagent
137(Roche) as recommended by the manufacturer. Stable PC3
138cells with depleted endogenous Brachyury expression were
139obtained following treatment with 5 mg/mL of puromycin
140(Sigma-Aldrich).
141Expression analysis by semiquantitative RT-PCR
142Total RNA was extracted from cell lines using TRIzol
143Reagent (Invitrogen S.A.). One microgram of RNA was
144reverse-transcribed using Phusion RT-PCRKit (Finnzymes),
145as recommended by themanufacturer. The primers used are
146presented in Supplementary Table S1.No amplificationwas
147obtained when RNA was mock-transcribed without adding
148reverse transcriptase.
149Western blot analysis
150Cells were lysed in buffer containing 50mmol/L Tris, pH
1517.6–8, 150 mmol/L NaCl, 5 mmol/L EDTA, 1 mmol/L Na3
152VO4, 10 mmol/L NaF, 10 mmol/L Na pyrophosphate, 1%
Translational Relevance
There is an emerging interest and demand to discover
new robust biomarkers of prostate cancer development
and prognostic. The presence of embryonic T-box tran-
scription factor Brachyury has been recently associated
with cancer aggressiveness andmetastasis. Currently, the
role of Brachyury in prostate cancer tumorigenesis is
unknown.Using a large cohort of humanprostate tissues
with different malignancy grades (normal, intraepithe-
lial lesions, primary tumors, and metastasis), in silico
data, and in vitro studies, we provide the first evidence of
aberrant Brachyury activation in primary and metastatic
prostate cancer and its clinical relevance. In addition, we
found that Brachyury nuclear expression predicts inva-
sive and metastatic prostate cancer behavior. Herein, we
suggest Brachyury as a novel biomarker of prostate
cancer metastasis and a potential therapeutic target for
patients with advanced prostate cancer.
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155 NP-40, and 1/7 of protease cocktail inhibitors (Roche).
156 Proteins were resolved on standard 12% SDS-PAGE gels,
157 transferred onto nitrocellulose membranes, and probed
158 with antibody against Brachyury (AF2085, R&D Systems)
159 and GAPDH (sc-69778, Santa Cruz Biotechnology, Inc.) at
160 4C overnight. Blot detection was done by chemilumines-
161 cence (ECL Western Blotting Detection Reagents, GE
162 Healthcare) using Chemidoc (Bio-Rad).
163 Immunofluorescence microscopy
164 Cells were plated on glass coverslips placed into 12-well
165 plates and allowed to adhere overnight. Cells were fixedwith
166 4% paraformaldehyde (PFA) in 1X PBS, washed, and per-
167 meabilizedwith0.1%TritonX-100. Then, cellswere blocked
168 in 10% FBS, labeled for 1 hour at room temperature with
169 primary anti-Brachyury antibody (sc-20109, Santa Cruz
170 Biotechnology, Inc.), washed, and incubated at room tem-
171 perature for 1 hour with a secondary anti-rabbit Alexa-488
172 antibody (Invitrogen-Molecular Probes). Coverslips were
173 mounted on microscope slides with Vectashield Mounting
174 Medium with DAPI (Vector Laboratories). Digital images
175 were recordedwithOlympusBX61 (OlympusCorporation).
176 Cell viability and proliferation assays
177 Colony formation assays were used to assess the survival
178 capacity of 22RV1, DU145, and PC3 cells with and without
179 Brachyury. A total of 1 103 cells per well were seeded into
180 6-well plates. After 15 days of culture, colonies formed were
181 fixed in 4% PFA, washed, stained with 0.05% crystal violet,
182 and manually counted.
183 MTS and bromodeoxyuridine (BrdUrd) assays were used
184 to evaluate the viability andproliferation capacity over time.
185 A total of 2 103 cells per well for 22RV1 and 1 103 cells
186 per well for DU145 and PC3were plated into 96-well plates
187 in triplicate and allowed to adhere overnight. After 6 hours
188 of starvation (RPMI only), viable or proliferative cells were
189 quantified using the Cell Titer96 Aqueous cell proliferation
190 (MTS, Promega) or Cell Proliferation ELISA, BrdUrd (col-
191 orimetric, Roche Applied Science) assay and this was the
192 value for time 0. After 24, 48, and 72hours, cell viability and
193 proliferation were again assessed. The results were calibrat-
194 ed to the starting value (time 0hours, considered as 100%of
195 viability/proliferation) as previously described (20).
196 Wound-healing migration assay
197 Cells were seeded in 12-well plates and cultured to at least
198 95% of confluence. Monolayer cells were washed with 1X
199 PBS and scraped with a plastic pipette tip and then incu-
200 bated with fresh RPMImedium. The "wounded" areas were
201 photographed by phase-contrast microscopy at different
202 time points. The relative migration distance was calculated
203 as described (20, 21).
204 Matrigel invasion assay
205 Matrigel invasion assayswere performedusing 8-mmpore
206 size BD BioCoat Matrigel Invasion Chambers (BD Bios-
207 ciences). Briefly, after rehydration with RPMI, 10% FBS, the
208 upper compartment of the chamber received 2.5 104 cells
210per well grown in RPMI only, whereas the lower compart-
211ment contained freshmedium supplementedwith 10%FBS
212and 10 ng/mL of EGF (Prepotech). After 22 hours of
213incubation, the upper surface of the filter was washed with
2141X PBS and fixed with 4% PFA. Then, residual cells were
215cleared with a cotton swab, the filter washed with 1X PBS,
216and invasive cells attached to the lower filter surface were
217mounted in Vectashield Mounting Medium with DAPI
218(Vector Laboratories). Images were recorded on an Olym-
219pus BX61 microscope (Olympus Corporation), and inva-
220sive cells counted using ImageJ software.
221IHC analysis
222Histologic slides with 4-mm-thick tissue sections were
223subjected to IHC analysis according to the streptavidin–
224biotin peroxidase complex system (UltraVision Large Vol-
225ume Detection System Anti-Polyvalent, HRP; LabVision
226Corporation), using the primary antibody raised against
227Brachyury (diluted 1:200; sc-20109, Santa Cruz Biotech-
228nology, Inc.) or against AMACR (diluted 1:50; 504R-16,
229Cell Marque). CD44 staining was performed using an anti-
230human CD44 antibody (diluted 1:100; 156-3C11, AbD
231Serotec) and detected using Vectastain Universal Elite ABC
232kit PK-6200 (Vector Laboratories). The negative control was
233treated identically but with omitted primary antibody.
234Sections were scored in a double-blind fashion for cyto-
235plasm expression following a semiquantitative criterion
236based on the intensity (0, negative; 1, weak; 2, moderate;
2373, strong) and percentage of cells stained (0, 0% of immu-
238noreactive cells; 1, <25% of immunoreactive cells; 2, 25%–
23950% of immunoreactive cells; and 3, >50% of immunore-
240active cells). Both components were considered for an
241overall semiquantitative staining score (range, 0–6). Sam-
242ples with scores 0, 1, and 2 were considered negative and
243those with scores 3–6 were considered positive. Tissues
244sections were separately evaluated for expression in the
245nucleus (25% nuclear staining was considered positive
246and cases with <25% of nuclear staining were considered
247negative).
248In silico analysis of Brachyury expression in the
249Oncomine database
250Brachyury mRNA expression was assessed in 7 prostate
251cancer datasets (LaTulippe, ref. 22; Varambally, ref. 23;
252Grasso, ref. 24; Taylor, ref. 25; Glinsky, ref. 26; Yu, ref. 27;
253TCGA, ref. 28; and Arredouani, ref. 29) from theOncomine
254database (30, 31). Categorization of patients with Brachy-
255ury-positive and Brachyury-negative prostate cancer was
256based on the log2 median-centered intensity values of
257Brachyury probes per study, and a linear model was fitted
258to estimate the association significance. Patient samples in
259each study with Brachyury expression values greater than its
260median intensity were grouped as Brachyury-positive and
261others were grouped as Brachyury-negative. Brachyury
262expression was further correlated with corresponding
263patient clinical data available.
264Microarray co-expression studies were extracted from the
265Oncomine database. Microarray expression profiles were
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268 clustered by functional importance and signaling pathways
269 using DAVID v6.7 bioinformatic tool (The Database for
270 Annotation, Visualization and Integrated Discovery;
271 refs. 32, 33).
272 Statistical analysis
273 Univariate (c2 test) and multivariate analyses (linear
274 regression model) were used to assess the correlations
275 between Brachyury expression and clinicopathologic fea-
276 tures from primary specimens. Pearson test was used to
277 evaluate the correlation between gene expression profiles.
278 Simple comparisons between 2 different conditions were
279 analyzed using the Student t test and, for comparison of 2
280 conditions over time, we used the 2-way ANOVA (Bonfer-
281 roni post-test). The statistical analysis was performed using
282 SPSS software (version 19.0) or using Prism GraphPad
283 software (version 5.0a). The level of significance in the
284 statistical analyses is indicated as , P < 0.05; , P < 0.01;
285 , P < 0.001.
286 Results
287 Brachyury protein is overexpressed in prostate cancer
288 and PIN lesions
289 Brachyury protein expression was assessed by IHC in a
290 series of 784 prostate tissues, including normal tissues, PIN
291 lesions, primary prostate cancer samples with different
292 Gleason scores and prostate cancer metastasis. Figure 1
293 shows representative results of intensity scores observed
294 for Brachyury expression. Normal prostate gland and adja-
295 cent nonneoplastic tissues presented absence or low levels
296 of Brachyury staining when compared with neoplastic tis-
298sues (Fig. 1A; Supplementary Fig. S1) and were therefore
299clustered in a single group, designated nonneoplastic tis-
300sues. Brachyury was expressed in the nuclei and/or cyto-
301plasm of epithelial cells in nonneoplastic tissues, PIN
302lesions, prostate cancer, and metastatic tissues (Fig. 1B–
303D; Supplementary Fig. S1). Overall, the number of cases
304presenting cytoplasm protein expression increased from
305nonneoplastic to prostate cancer and PIN lesions and to
306metastasis (33.9%, 55.2%, 61.5%, and 100% of positive
307cases, respectively; P < 0.001; Fig. 2A). Brachyury nuclear
308staining was present in a comparable number of cases in
309nonneoplastic (25.0%), PIN lesions (38.6%), and prostate
310cancer cases (25.4%), in contrast to 100% of metastatic
311tissue samples Q3(P < 0.001; Figs. 1vi and 2A). Interestingly,
312Brachyury was also detected in the stroma (Supplementary
313Fig. S1) with a significant reduction of stroma-positive
314cases from nonneoplastic tissues (52.6%), to PIN lesions
315(44.2%), and to prostate cancer (14.2%; P < 0.001; Fig. 2A),
316indicating a possible role for Brachyury in prostate cancer
317tumor tissue microenvironment.
318Heatmapanalysis of overall Brachyury protein expression
319showed that Brachyury is remarkably overexpressed in
320PIN, prostate cancer, and metastatic prostate tissues when
321compared with nonneoplastic tissues (Fig. 2B). The higher
322expression profile was found in metastasis with scores
323consistently 4.
324Brachyury protein overexpression is associated with
325poor prognosis in prostate cancer
326The clinical impact of Brachyury protein expression levels
327was further explored in our cohort of 409 primary prostate
Figure 1. BrachyuryQ4 expression in
nonneoplastic tissues, PIN lesions,
prostate cancer, and metastatic
tissues. Brachyury is absent or
expressed at low levels in
nonneoplastic tissues (A, normal
gland). Primary prostate cancer
Brachyury-positive cases can
exhibited only cytoplasm staining
(B) or both cytoplasm and nuclear
staining (C). Metastatic lesion
showing both cytoplasm and
nuclear (D).Magniﬁcation,200 (A)
and 400 (B–D).
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330 cancer. Univariate outcome analysis showed that Brachy-
331 ury-positive cases (scores  3) are significantly (P < 0.001)
332 associated with the prostate cancer biomarker a-methyla-
333 cyl-CoA racemase (AMACR; Supplementary Table S2). Bra-
334 chyury-positive cases correlated with highly undifferentiat-
335 ed prostate cancer tumors (P ¼ 0.007, Table 1) and, con-
336 cordantly, a strong tendency to be associated with stem cell
337 marker CD44 was observed (P ¼ 0.054; Supplementary
338 Table S2). Importantly, Brachyury protein levels increased
339 with the Gleason score (P < 0.027, Table 1; P < 0.01,
340 Supplementary Fig. S2). To evaluate the clinical impact of
341 the presence of Brachyury in the nucleus, a comparison
342 between Brachyury nuclei–positive and nuclei-negative in
343 prostate cancer–positive cases was performed (nonneoplas-
344 tic tissues, n ¼ 76; PIN lesion, n ¼ 88; prostate cancer, n ¼
345 228;metastasis,n¼9). Primary prostate cancer tumorswith
346 nuclear Brachyury staining were significantly associated
347 with perineural invasion (P ¼ 0.046) and with capsular
348 invasion (P ¼ 0.025; Table 1), which is in agreement
349 with predominant nuclear expression in metastasis (Figs. 1
350 and 2). Because Gleason scores and pT stage are known
351 prognostic biomarkers, we performed multivariate analysis
352 to determine whether high Brachyury expression has
353 an independent statistical value. We observed that Bra-
354 chyury is significantly associated with capsular invasion
355 (P ¼ 0.027, Table 1) on primary prostate cancer samples.
356 No significant correlations were found for Brachyury
357 staining in stroma with clinicopathologic parameters by
358 univariate analysis (Table 1). Yet, the multivariate analysis
359 showed a significant association with capsular invasion
360 (P ¼ 0.030, Table 1), indicating the possible role of Bra-
361 chyury on tumor microenvironment.
362 Altogether, these data suggest that high Brachyury levels
363 are associatedwith patient’s poor outcome and indicate that
364 nuclear Brachyury staining in prostate cancer is an inde-
365 pendent prognostic factor.
366 In silico validation of the role of Brachyury expression
367 in prostate cancer aggressive behavior
368 To corroborate our findings, we extended the analysis to
369 microarray profiling datasets of prostate cancer tissues
370 available on the Oncomine database (30, 31). Brachyury
371 mRNA expression was analyzed in 6 independent prostate
372 cancer datasets (LaTulippe, ref. 22; Varambally, ref. 23;
373 Grasso, ref. 24; Taylor, ref. 25; Yu, ref. 27; and Arredouani,
374 ref. 29) comprising a total of 97 normal prostate gland, 304
375 prostate cancer, and 83 prostate cancer metastasis samples.
376 We found that Brachyury was significantly overexpressed in
378prostate tissues in multiple microarray cancer profiling
379datasets, in particular in metastatic prostate cancer (Fig.
3802C). Thiswas concordantwith our protein analysis reported
381above. Importantly, although multiple probes were used to
382determine Brachyury mRNA levels in these datasets
383(23996_at, 206524_at, A_24_P63642, 7679), they all con-
384sistently showed thatBrachyuryoverexpression is a common
385event in primary and metastatic prostate cancer (Fig. 2C).
386We next assessed the impact of Brachyury in prostate
387cancer prognosis at the mRNA level, exploring the micro-
388array profiling datasets of localized prostate tumors with
389clinical data from Oncomine (Table 2). Univariate statisti-
390cal analysis revealed that high levels of Brachyury expression
391correlated with higher (>7) Gleason scores for the Taylor
392(25), Glinsky (26), and LaTulippe (22) datasets (P¼ 0.043,
393P ¼ 0.042, and P ¼ 0.049, respectively; Table 2). In agree-
394ment with protein IHC levels, the percentage of Brachyury-
395positive cases directly increased with the Gleason score (P <
3960.05; Supplementary Fig. S2). In addition, high Brachyury
397mRNA levels correlated with pT (Yu, ref. 27; P¼ 0.033) and
398N stage (Taylor, ref. 25; P¼ 0.043), biochemical recurrence
399(Taylor, ref. 25; P ¼ 0.048), capsular invasion and extra-
400prostatic extension (Glinsky, ref. 26; P ¼ 0.002 and 0.007,
401respectively; Table 2). A similar tendency could also be
402observed in the other datasets. In the multivariate analysis,
403we found that high Brachyury mRNA levels still correlate
404with capsular invasion and extraprostatic extension
405(Glinsky, ref. 26; P ¼ 0.001 and 0.032, respectively) and
406with biochemical recurrence (TCGA, ref. 28; P ¼
4070.004; Table 2).
408Prostate cell lines recapitulate Brachyury expression
409profiles of human prostate cancer tissues
410To explore the biologic role of Brachyury in prostate
411cancer aggressiveness, 5 prostate cancer cell lines (PNT2,
41222RV1, LnCaP, PC3, and DU145), representative of differ-
413ent degrees of prostate cancer progression,were screened for
414Brachyury expression by semiquantitative RT-PCR and
415Western blot analyses. Brachyury protein subcellular local-
416izationwas additionally evaluated by immunofluorescence.
417We observed an absence of Brachyury at both mRNA and
418protein levels in the nonmalignant prostate cell line (PNT2)
419and in the primary prostate cancer cell line (22RV1; Sup-
420plementary Fig. S3A). In contrast, the metastatic cell lines
421LNCaP and PC3 showed strong nuclear and cytoplasm
422Brachyury expression both at mRNA and at protein levels
423(Supplementary Fig. S3A). The metastatic DU145 cell line
424was negative for mRNA by conventional RT-PCR but still
Figure 2. Brachyury is overexpressed in prostate cancer (PCa) and metastatic tissues. A, representation of Brachyury-positive cases according to Brachyury
localization; left, overall score for cytoplasm staining; middle, presence in nucleus; right, presence in stromal cells. B, heatmap of protein levels in
tissuemicroarray prostate samples (range, 0–6). There is a predominant blue staining (negative, score < 3) in normal tissues and orange/red staining (positive,
score  3) in PIN, prostate cancer, and metastasis tissues. Each column represents a single case and it is possible verify the respective normal adjacent
tissue or PIN lesion of a speciﬁc prostate cancer case. In the majority of the cases, an increased expression from normal to PIN and to prostate cancer
can be appreciated in the same patient. C, analysis of microarray expression data for Brachyury levels from the Oncomine database. Log2 median-
centered ratio expression is present for 6 different datasets (Yu, ref. 27; Varambally, ref. 23; Grasso, ref. 24; Taylor, ref. 25; Latullipe, ref. 22; andArredouani, ref.
29) representing 4 different probes for Brachyury detection (34996_at, 206524_at, A_24_P63642, and 7679). Brachyury is commonly overexpressed in
prostate cancer tissues and PCa metastasis. , P < 0.05; , P < 0.01; , P < 0.001.
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427 exhibited low levels of nuclear protein expression (Supple-
428 mentary Fig. S3A). These findings indicate that prostate cell
429 lines are good models to study the functional role of
430 Brachyury in prostate cancer cells, as they recapitulate the
431 expression profiles found in human clinical samples.
432 Brachyury promotes prostate cancer aggressiveness in
433 vitro
434 To address whether the modulation of Brachyury expres-
435 sion influences the tumorigenic properties of prostate can-
436 cer cells, Brachyury was overexpressed in primary (22RV1)
437 and metastatic (DU145) prostate cancer cell lines. Success-
438 ful ectopic overexpression was obtained upon transfection
439 of both cell lines with the pcBrachyury expression vector
440 and Brachyury protein exhibited nuclear localization (Sup-
441 plementary Fig. S3B). To investigate the effect of Brachyury
442 inhibition, a specific short-hairpin clone (shBrachy.1) was
443 used to deplete Brachyury in a positive metastatic prostate
444 cell line (PC3; Supplementary Fig. S3B).
445 We initially studied the biologic role of Brachyury on
446 prostate cancer cell viability and proliferation (Fig. 3A;
447 Supplementary Fig. S4A). pcBrachyury prostate cells had
448 a significant (P < 0.05) viability advantage over time (MTS
449 assay) compared with the cells transfected with the empty
450 vector (4/T0). Colony formation assays revealed a signifi-
451 cant (P < 0.05) increase in the number of the colonies
452 formed in the pcBrachyury-transfected cells when com-
453 pared with the control cells (Fig. 3A, Supplementary Fig.
455S4A). The opposite findings were obtained with Brachyury
456depletion in shBrachy.1-PC3 cells (P < 0.05; Fig. 3A). To
457determine whether this viability advantage was due to
458higher proliferation rates, we analyzed BrdUrd incorpo-
459ration during S-phase of the cell cycle. The presence of
460Brachyury, whether endogenous or exogenously overex-
461pressed, promoted higher rates of proliferation over time
462(P < 0.05; Fig. 3A; Supplementary Fig. S4A). We further
463performed wound migration and Matrigel invasion assays
464in the transfected cell lines and observed that both 22RV1
465and DU145 pcBrachyury cells had a higher migratory
466capacity over time and increased cell invasion capability
467than the empty vector cells (P < 0.05; Fig. 3B; Supplemen-
468tary Fig. S4B). When Brachyury was depleted in an endog-
469enously positive cell line, we were able to attenuate the
470aggressive behavior (P < 0.05; Fig. 3B).
471To characterize themolecular players underlying prostate
472aggressiveness in vitro, we studied the expression profile of
473some key genes involved in EMT, migration, and stemness
474processes. We observed that Brachyury expression was asso-
475ciated with a decrease of the epithelial marker E-cadherin
476and concomitant increased expression of mesenchymal
477genes (N-cadherin, fibronectin, and Snail), as well as upre-
478gulation of metalloprotease MMP14 (Supplementary Fig.
479S5). Concordantly with IHC analysis in human prostate
480cancer (Supplementary Table S2), Brachyury overexpres-
481sionwas associatedwith an increased expression of the stem
482cell marker CD44 (Supplementary Fig. S5).
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Figure 3. Evaluation of biologic role of Brachyury in prostate cancer cell lines. A, effect of Brachyury on viability and proliferation of prostate cells (22RV1 and
PC3) evaluated byMTS, colony formation, and BrdUrd assays. B, wound-healing andMatrigel invasion assays were used to evaluate the role of Brachyury in
migration and invasion, respectively. The presence of Brachyury correlated with increased cell viability, proliferation, migration, and invasion. Red lines and
black bars, Brachyury-positive cell lines; blue lines andwhite bars, Brachyury-negative or Brachyury-depleted cell lines. ,P < 0.05; ,P < 0.01; ,P < 0.001.
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485 Genes co-expressed with Brachyury in microarray
486 analyses are associated with tumorigenic clusters
487 We clustered the genes co-expressed with Brachyury
488 in prostate tissues available at the Oncomine database
489 (30, 31) by their functional role and importance in signal
490 transduction pathways using theDAVIDbioinformatic tool
492(Fig. 4A). We found that the majority of genes co-expressed
493with Brachyury were functionally clustered in the categories
494of immune response, cell membrane/receptor activity,
495development, cell motility, and chemotaxis pathways in
496cancer and response to hormone stimulus. A subanalysis
497by KEGG signaling pathways revealed that Brachyury
Figure 4. In silico analysis of genes co-expressed with Brachyury in prostate cancer. Microarray expression proﬁles of Brachyury co-expressed genes were
clustered by functional role and signaling pathways using DAVID in silico tool. The functional clusters organized by enrichment score (A) and the KEGG
signaling pathway analysis (B). Brachyury co-expressed genes are associated with pathways involved in tumor aggressiveness, namely, in immune cell
response, positive cell-cycle regulation, cell motility, and chemotaxis. C, in silico analysis indicates an inverse correlation between Brachyury and epithelial
marker E-cadherin and a direct correlation with several genes involved with EMT (ﬁbronectin,MMP14,MMP24, Snail, IL8, and TGFb1). NS, not signiﬁcant.
Pinto et al.
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500 co-expressed genes are grouped in pathways associatedwith
501 higher aggressiveness, namely, pathways in cancer, positive
502 cell-cycle regulation, and immune response (Fig. 4B). These
503 analyses strongly point to a role of Brachyury, not only in
504 cellmigration and invasion but also as a regulator of the cell
505 cycle and in cancer microenvironment metabolism. Impor-
506 tantly, we found that the levels of Brachyury expression
507 in prostate cancer tissues are directly correlated with those
508 of IL8 and TGFb1 (Fig. 4C), which are involved in EMT
509 and cancer microenvironment modulation, as previously
510 described (13, 14). Accordingly, there is a correlation of
511 Brachyury expressionwith the expression of genes associated
512 with EMT process (like fibronectin) and migration (MMP14;
513 MMP24; Fig. 4C) that support our expression analysis
514 (Supplementary Fig. S5).
515 Discussion
516 The T-box transcription factor Brachyury was initially
517 discovered for its role in mouse mesoderm development
518 and differentiation (34). This involves massive conversion
519 of epithelial cells intomigratory and invasivemesenchymal
520 cells during gastrulation via a process known as EMT (2, 4).
521 Several reports have demonstrated that EMT is critical for
522 prostate cancer progression, as acquisition of mesenchymal
523 features may favor dissemination and resistance to therapy
524 (35). High levels of Brachyury have previously been
525 reported in various types of cancer (5–9, 11) and a phase
526 I clinical trial of a vaccine targeting Brachyury-positive
527 tumors (GI-6301) is currently underway (36, 37). Although
528 prostate cancer is a leading cause of cancer-related deaths in
529 men worldwide, a characterization of Brachyury biologic
530 role in prostate tumorigenesis is missing.
531 Our study reports for the first time that the transcription
532 factor Brachyury is aberrantly overexpressed across prostate
533 malignancy and, in particular, nuclear Brachyury staining is
534 associated with prostate invasion and prostate metastatic
535 tissues. Our findings indicate Brachyury as an independent
536 prognostic factor in prostate cancer. The role of Brachyury
537 nuclear staining in metastasis was demonstrated in other
538 tumor types, such as colorectal, lung cancer, and oral
539 squamous cell carcinoma (6–9). Herein, we also found
540 that cytoplasm immunostaining in prostate cancer is asso-
541 ciated with prostate cancer biomarker AMACR and with
542 highly aggressive tumors. The role of Brachyury in the cell
543 cytoplasm remains to be elucidated, yet, we canhypothesize
544 that it interacts with other proteins and in this way regulates
545 cell behavior in a nontranscription manner.
546 It has been shown that Brachyury expression can influ-
547 ence tumor microenvironment through the release of sol-
548 uble factors that could induce adjacent epithelial tumor
549 cells to undergo an EMT and acquire metastatic potential
550 (14). In prostate cancer, the activation and secretion to the
551 extracellular environment of soluble factors that mediate
552 the cross-talk between tumor cells and tumor stroma, such
553 as interleukins and growth factors, has been reported to play
554 a role in tumor progression (13, 14, 38–40). Our analysis
555 confirm a previously result that demonstrated that Brachy-
557ury increases the expression and secretion of TGFb1 in a
558prostate cell line (13). However, the influence of Brachyury
559expression in stromal cells has not yet been characterized.
560To our knowledge, we provide the first evidence for
561decreased Brachyury expression in stromal cells with pros-
562tate malignancy, at variance with the reported upregulation
563in tumor cells. Therefore, we can hypothesize that Brachy-
564ury has different roles in stromal and tumor cells and that it
565could be involved in the regulation of tumor microenvi-
566ronment. In addition, we found that the majority of Bra-
567chyury co-expressed genes are involved in immune or
568metabolic processes.
569By Brachyury overexpression and downregulation in pros-
570tate cancer cell lines, we demonstrated its role in tumor cell
571migration and invasion, as well as in cell viability and
572proliferation. Our findings were further corroborated by an
573in silico analysis withmultiple genes functionally clustered in
574pathways related with cell motility and cell proliferation. A
575study performed by Shomoda and colleagues demonstrated
576that ablationofBrachyury in adenoid cystic carcinoma (ACC)
577cells decreased the number of metastasis and tumor size in
578vivo (11).Moreover, depletionofBrachyury in chordomacells
579promotes a complete block of cell proliferation (41). An
580opposite role for Brachyury in cell proliferation was demon-
581strated in lung and colorectal cell lines by Huang and
582collaborators, where Brachyury blocks cell cycle progression
583and mediates tumor resistance to conventional antitumor
584therapies (15). Therefore, it can be deduced that the role of
585Brachyury may be tissue-specific or cell-type–dependent.
586Brachyury seems to be a key driver of EMT in various
587human tumors by increasing expressionof genes suchasSlug,
588Snail,MMPs, IL8, andTGFb1 (6, 9, 13–15, andcurrent study).
589A possible link between cells undergoing EMT and cells with
590"stem cell–like" properties was recently described (42). The
591role of Brachyury in conferring stemness properties was
592already demonstrated in colorectal cancer cells (10) and in
593ACC cells (11). The present study shows that Brachyury is
594more represented in CD44þ prostate tissues, and ectopic
595Brachyuryoverexpression in vitropromotesCD44expression.
596Because CD44þ prostate tumors are more resistant to the
597currently used therapies (43, 44),we speculate that Brachyury
598could have a role in prostate cancer therapy resistance. Future
599studies are warranted to elucidate this hypothesis.
600In conclusion, thepresentwork reports increased levels of
601Brachyury expression in localized and metastatic prostate
602cancer, with clinicopathologic significance and evidences a
603role for Brachyury in promoting prostate cancer cell growth
604and invasion. Our work further suggests new roles for
605Brachyury in prostate cancer, namely, in tumor microenvi-
606ronment regulation and possibly in immune response.
607Clinical applicable prognostic biomarkers are needed for
608clinical management of patients with prostate cancer and
609our study positions Brachyury as a putative independent
610prognostic biomarker in prostate cancer and a possible
611therapeutic target for advanced prostate tumor patients.
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